Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oxidative phosphorylation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Oxidative phosphorylation. Displaying page 1 of 1.
    EudraCT Number: 2007-005371-34 Sponsor Protocol Number: 2 39 00240 133 Start Date*: 2008-03-18
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study.
    Medical condition: Out patient suffering from friedreich ataxia aged from 12 to 20 years
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000192-37 Sponsor Protocol Number: 2019_0007 Start Date*: 2021-10-04
    Sponsor Name:Hôpital Foch
    Full Title: Oxidative Phosphorylation Targeting In Malignant glioma Using Metformin plus radiotherapy temozolomide
    Medical condition: Patients with a diagnosis of Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003124-16 Sponsor Protocol Number: KH176-204 Start Date*: 2021-01-12
    Sponsor Name:Khondrion B.V.
    Full Title: A randomized placebo controlled, double-blind phase II study to explore the safety, efficacy and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease.
    Medical condition: Genetically confirmed mitochondrial disease
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004557-24 Sponsor Protocol Number: UKM17_0056 Start Date*: 2019-07-29
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003481-25 Sponsor Protocol Number: DIMAT-MS Start Date*: 2015-05-13
    Sponsor Name:Universitätsklinikum Münster
    Full Title: A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis
    Medical condition: relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006290-25 Sponsor Protocol Number: 4141 Start Date*: 2012-05-03
    Sponsor Name:Copenhagen University Hospital Rigshospitalet, The Heart Center - Department of Thoracic Surgery
    Full Title: The Pulmonary Protection Trial (PP-Trial) Pulmonary dysfunction after open heart surgery: Randomized clinical trial with focus on lung-protective interventions
    Medical condition: Dysfunction of the lungs after open heart surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 07:20:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA